Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile

Endocrinology

Volumn 149, Issue 2, 2008, Pages 827-835

  DeBoer, Mark D ^a   Zhu, Xinxia ^b   Levasseur, Peter R ^b   Inui, Akio ^c   Hu, Zhaoyong ^d   Han, Guofeng ^d   Mitch, William E ^d   Taylor, John E ^e   Halem, Heather A ^e   Dong, Jesse Z ^e   Datta, Rakesh ^e   Culler, Michael D ^e   Marks, Daniel L ^b,f  

^a UNIVERSITY OF VIRGINIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e IPSEN   (France)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALPHA INTERMEDIN; BIM 28125; BIM 28131; CYTOKINE; GHRELIN; GROWTH HORMONE SECRETAGOGUE RECEPTOR; INTERLEUKIN 1 RECEPTOR; MYOSIN ADENOSINE TRIPHOSPHATASE; PROOPIOMELANOCORTIN; PROPROTEIN CONVERTASE 2; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FOOD INTAKE; LEAN BODY WEIGHT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; UREMIA;

ABSORPTIOMETRY, PHOTON; ANIMALS; BODY WEIGHT; CACHEXIA; CYTOKINES; DACTINOMYCIN; DISEASE MODELS, ANIMAL; EATING; GENE EXPRESSION; GHRELIN; GROWTH HORMONE; INFLAMMATION; INSULIN-LIKE GROWTH FACTOR I; MALE; MUSCLE, SKELETAL; NEPHRECTOMY; NEUROPEPTIDES; RATS; RATS, INBRED F344; RECEPTORS, GHRELIN; RENAL INSUFFICIENCY, CHRONIC; RNA, MESSENGER;

EID: 38549149911     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1046     Document Type: Article

References (63)

1. DeBoer MD, Marks DL 2006 Therapy insight: use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab 2:459-466
2. Mak RH, Cheung W 2006 Energy homeostasis and cachexia in chronic kidney disease. Pediatr Nephrol 21:1807-1814
3. Bailey JL, Wang X, England BK, Price SR, Ding X, Mitch WE 1996 The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 97:1447-1453
4. Chertow GM, Ackert K, Lew NL, Lazarus JM, Lowrie EG 2000 Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. Kidney Int 58:2512-2517
5. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE 2004 Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113:115-123
6. Kaysen GA, Dubin JA, Muller HG, Rosales L, Levin NW, Mitch WE 2004 Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 65:1408-1415
7. Mitch WE 2002 Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin Invest 110:437-439
8. Pickering WP, Price SR, Bircher G, Marinovic AC, Mitch WE, Walls J 2002 Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 61:1286-1292
9. Benigni A, Remuzzi G 2001 How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis 37:S21-S24
10. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL 1998 Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32:107-114
11. Kaysen GA 2005 Effects of inflammation on plasma composition and endothelial structure and function. J Ren Nutr 15:94-98
12. Maruyama Y, Stenvinkel P, Lindholm B 2005 Role of interleukin-1β in the development of malnutrition in chronic renal failure patients. Blood Purif 23:275-281
13. Mitch WE, Du J, Bailey JL, Price SR 1999 Mechanisms causing muscle proteolysis in uremia: the influence of insulin and cytokines. Miner Electrolyte Metab 25:216-219
14. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA 1994 Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45:890-896
15. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimburger O, Lindholm B, Bergstrom J 2002 Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13(Suppl 1):S28-S36
16. DeBoer MD, Marks DL 2006 Cachexia: lessons from melanocortin antagonism. Trends Endocrinol Metab 17:199-204
17. Mak RH, Cheung W, Cone RD, Marks DL 2006 Mechanisms of disease: cytokine and adipokine signaling in uremic cachexia. Nat Clin Pract Nephrol 2:527-534
18. Marks DL, Ling N, Cone RD 2001 Role of the central melanocortin system in cachexia. Cancer Res 61:1432-1438
19. Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant WF, Cowley MA, Marks DL 2007 Regulation of central melanocortin signaling by interleukin-1β. Endocrinology 148:4217-4225
20. Bossola M, Muscaritoli M, Tazza L, Panocchia N, Liberatori M, Giungi S, Tortorelli A, Rossi Fanelli F, Luciani G 2005 Variables associated with reduced dietary intake in hemodialysis patients. J Ren Nutr 15:244-252
21. Chertow GM, Johansen KL, Lew N, Lazarus JM, Lowrie EG 2000 Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 57:1176-1181
22. Dwyer JT, Larive B, Leung J, Rocco M, Burrowes JD, Chumlea WC, Frydrych A, Kusek JW, Uhlin L 2002 Nutritional status affects quality of life in Hemodialysis (HEMO) Study patients at baseline. J Ren Nutr 12:213-223
23. Shinaberger CS, Kilpatrick RD, Regidor DL, McAllister CJ, Greenland S, Kopple JD, Kalantar-Zadeh K 2006 Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 48:37-49
24. Sreedhara R, Avram MM, Blanco M, Batish R, Avram MM, Mittman N 1996 Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis 28:937-942
25. Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M 2004 Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer 101:1090-1098
26. Wang AY, Sea MM, Tang N, Sanderson JE, Lui SF, Li PK, Woo J 2004 Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 15:3134-3143
27. DeBoer MD 2007 Melanocortin interventions in cachexia: how soon from bench to bedside? Curr Opin Clin Nutr Metab Care 10:457-462
28. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S 2001 A role for ghrelin in the central regulation of feeding. Nature 409:194-198
29. Sun Y, Wang P, Zheng H, Smith RG 2004 Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 101:4679-4684
30. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, Smith RG, Cunningham GR, Marcelli M 2005 Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90:2920-2926
31. Hataya Y, Akamizu T, Hosoda H, Kanamoto N, Moriyama K, Kangawa K, Takaya K, Nakao K 2003 Alterations of plasma ghrelin levels in rats with lipopolysaccharide-induced wasting syndrome and effects of ghrelin treatment on the syndrome. Endocrinology 144:5365-5371
32. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, Kitakaze M, Miyatake K, Kangawa K 2004 Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110:3674-3679
33. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC, Bloom SR 2004 Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2832-2836
34. Rodriguez Ayala E, Pecoits-Filho R, Heimburger O, Lindholm B, Nordfors L, Stenvinkel P 2004 Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant 19:421-426
35. DeBoer MD, Zhu XX, Levasseur P, Meguid MM, Suzuki S, Inui A, Taylor JE, Halem HA, Dong JZ, Datta R, Culler MD, Marks DL 2007 Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 148:3004-3012
36. Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A 2005 Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab 288:E486-E492
37. Datta R DJ, Taylor JE, Halem HA, Zhang J, Strassburg, Tschop M, Springer J, Anker S, Marks D, Culler MD, Ghrelin and ghrelin analogs. Proc Third International Cachexia Conference, Rome, Italy, 2005
38. Halem HA TJ, Dong JZ, Eynon J, Zhang J, Datta R, Culler MD, A unique agonist of the GHS-1a receptor that induces an enhanced biphasic pattern of weight gain. Program of the 86th Annual Meeting of The Endocrine Society, New Orleans, LA, 2004, p 34 (Abstract P2-512)
39. Halem HA TJ, Datta R, Mussulli L, Eynon J, Zhang J, Dong JZ, Culler MD, BIM-28131, a uniquely potent agonist of the GHS-1a receptor that is highly efficacious in stimulating body weight gain and food intake. Program of the 87th Annual Meeting of The Endocrine Society, San Diego, CA, 2005, p 407 (Abstract P2-210)
40. Bailey JL, Zheng B, Hu Z, Price SR, Mitch WE 2006 Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 17:1388-1394
41. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P 2005 Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115:451-458
42. Wang X, Hu Z, Hu J, Du J, Mitch WE 2006 Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 147:4160-4168
43. Kalantar-Zadeh K, Balakrishnan VS 2006 The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodial Int 10:315-325
44. Xue JL, Ma JZ, Louis TA, Collins AJ 2001 Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12:2753-2758
45. Bergstrom J 1995 Nutrition and mortality in hemodialysis. J Am Soc Nephrol 6:1329-1341
46. Burrowes JD, Cockram DB, Dwyer JT, Larive B, Paranandi L, Bergen C, Poole D 2002 Cross-sectional relationship between dietary protein and energy intake, nutritional status, functional status, and comorbidity in older versus younger hemodialysis patients. J Ren Nutr 12:87-95
47. Hansen TB, Gram J, Jensen PB, Kristiansen JH, Ekelund B, Christiansen JS, Pedersen FB 2000 Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 53:99-107
48. Johansen KL, Mulligan K, Schambelan M 1999 Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 281:1275-1281
49. Cone RD 2005 Anatomy and regulation of the central melanocortin system. Nat Neurosci 8:571-578
50. Helwig M, Khorooshi RM, Tups A, Barrett P, Archer ZA, Exner C, Rozman J, Braulke LJ, Mercer JG, Klingenspor M 2006 PC1/3 and PC2 gene expression and post-translational endoproteolytic pro-opiomelanocortin processing is regulated by photoperiod in the seasonal Siberian hamster (Phodopus sungorus). J Neuroendocrinol 18:413-425
51. Jing E, Nillni EA, Sanchez VC, Stuart RC, Good DJ 2004 Deletion of the Nhlh2 transcription factor decreases the levels of the anorexigenic peptides α-melanocyte-stimulating hormone and thyrotropin-releasing hormone and implicates prohormone convertases I and II in obesity. Endocrinology 145:1503-1513
52. Laurent V, Jaubert-Miazza L, Desjardins R, Day R, Lindberg I 2004 Biosynthesis of proopiomelanocortin-derived peptides in prohormone convertase 2 and 7B2 null mice. Endocrinology 145:519-528
53. Scarlett JM JE, Enriori PJ, Bowe DD, Batra AK, Grant WF, Cowley MA, Marks DM 2007 Regulation of central melanocortin signaling by interleukin-1β. Endocrinology 148:4217-4225
54. Cheunsuang O, Morris R 2005 Astrocytes in the arcuate nucleus and median eminence that take up a fluorescent dye from the circulation express leptin receptors and neuropeptide Y Y1 receptors. Glia 52:228-233
55. Lecker SH, Solomon V, Mitch WE, Goldberg AL 1999 Muscle protein break-down and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 129:227S-237S
56. Mitch WE, Goldberg AL 1996 Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335:1897-1905
57. Belizario JE, Lorite MJ, Tisdale MJ 2001 Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer 84:1135-1140
58. Libera LD, Vescovo G 2004 Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimaeric view of inflammation? Curr Opin Clin Nutr Metab Care 7:435-441
59. Raj DS, Shah H, Shah VO, Ferrando A, Bankhurst A, Wolfe R, Zager PG 2003 Markers of inflammation, proteolysis, and apoptosis in ESRD. Am J Kidney Dis 42:1212-1220
60. Vescovo G, Zennaro R, Sandri M, Carraro U, Leprotti C, Ceconi C, Ambrosio GB, Dalla Libera L 1998 Apoptosis of skeletal muscle myofibers and interstitial cells in experimental heart failure. J Mol Cell Cardiol 30:2449-2459
61. Workeneh BT, Rondon-Berrios H, Zhang L, Hu Z, Ayehu G, Ferrando A, Kopple JD, Wang H, Storer T, Fournier M, Lee SW, Du J, Mitch WE 2006 Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. J Am Soc Nephrol 17:3233-3239
62. Reaich D, Channon SM, Scrimgeour CM, Daley SE, Wilkinson R, Goodship TH 1993 Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol 265:E230-E235
63. Takeda R, Nishimatsu H, Suzuki E, Satonaka H, Nagata D, Oba S, Sata M, Takahashi M, Yamamoto Y, Terauchi Y, Kadowaki T, Kangawa K, Kitamura T, Nagai R, Hirata Y 2006 Ghrelin improves renal function in mice with ischemic acute renal failure. J Am Soc Nephrol 17:113-121